Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 13 sources cited
Key Takeaways
- Medicare Part D cannot cover prescription drugs whose primary indication is weight loss, under the Social Security Act Section 1860D-2(e)(2)(A) exclusion that has been in place since 2003.
- Medicare Part D does cover GLP-1 medications for type 2 diabetes (Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza), with prior authorization in most plans.
- The March 2024 Wegovy approval for cardiovascular risk reduction created the first Medicare Part D coverage pathway for a semaglutide-class drug in patients with established CVD and obesity.
- The December 2024 Zepbound approval for moderate-to-severe sleep apnea opened a second Part D coverage pathway for tirzepatide.
- Medicare Advantage plans follow Part D coverage rules for prescription drug benefits and don't have authority to add weight-loss-only coverage.
- Older weight-loss drugs (phentermine, orlistat, naltrexone-bupropion, phentermine-topiramate) are not covered by traditional Medicare Part D when prescribed for weight loss.
Direct answer (40-60 words)
Medicare Part D cannot cover weight-loss drugs prescribed solely for weight loss, under a 2003 statutory exclusion. However, Medicare does cover GLP-1s like Ozempic and Mounjaro for type 2 diabetes, Wegovy for cardiovascular risk reduction in qualifying patients, and Zepbound for moderate-to-severe sleep apnea in patients with obesity (since the late-2024 FDA approvals).
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- Why Medicare won't cover weight loss drugs
- The four exceptions to the rule
- What Medicare Part D covers in 2026
- Diabetes coverage pathway: Ozempic, Mounjaro, others
- Cardiovascular risk pathway: Wegovy
- Sleep apnea pathway: Zepbound
- Older weight-loss drugs and Medicare
- Medicare Advantage and Part C rules
- Medigap, supplement plans, and weight-loss drugs
- Cost expectations even when covered
- Alternatives if Medicare excludes your medication
- FAQ
- Sources
- Footer disclaimers
Why Medicare won't cover weight loss drugs
The Medicare Modernization Act of 2003 created the Part D prescription drug benefit. The same law explicitly excluded several drug categories, including:
- Drugs used to promote fertility.
- Drugs used for cosmetic purposes or hair growth.
- Drugs used for the symptomatic relief of cough and colds.
- Drugs used for weight loss, weight gain, or anorexia.
- Prescription vitamins and minerals (with limited exceptions).
- Erectile dysfunction drugs (later partially relaxed).
The weight-loss exclusion is codified at 42 CFR 423.100 and Social Security Act Section 1860D-2(e)(2)(A). It applies to all Medicare Part D plans, all Medicare Advantage prescription drug plans, and to the Veterans Affairs Tricare-for-Life prescription benefit by reference.
The reasoning at the time: weight-loss drugs of the early 2000s (orlistat, phentermine, sibutramine) were viewed as cosmetic or lifestyle medications rather than treatments for chronic disease. The science has shifted dramatically since the 2021 STEP-1 trial on semaglutide and the 2022 SURMOUNT-1 trial on tirzepatide, but the statute hasn't been amended.
There have been multiple congressional attempts to amend the exclusion. The Treat and Reduce Obesity Act (TROA), introduced repeatedly since 2013, would allow Part D coverage of FDA-approved chronic weight-management medications. As of Q1 2026, TROA has not passed.
The four exceptions to the rule
The exclusion applies to drugs prescribed primarily for weight loss. It doesn't apply when the drug is prescribed for a different FDA-approved indication, even if weight loss is a beneficial side effect. The four exceptions:
Exception 1: Type 2 diabetes (longstanding). Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, and Bydureon are all FDA-approved for type 2 diabetes. Part D plans cover them for that indication, often with prior authorization.
Exception 2: Cardiovascular risk reduction in patients with established CVD and obesity (Wegovy, since March 2024). The SELECT trial (Lincoff et al., NEJM 2023) showed semaglutide reduced major adverse cardiovascular events by 20% in patients with established CVD and BMI of 27 or higher. The FDA expanded Wegovy's indication in March 2024. This created a Part D coverage pathway when the drug is prescribed for CVD risk reduction (not just weight loss).
Exception 3: Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, since December 2024). The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024) showed tirzepatide significantly improved AHI in patients with moderate-to-severe OSA and obesity. The FDA approved Zepbound for OSA in December 2024. Some Part D plans began covering Zepbound for OSA in 2025 with prior authorization (sleep study documentation required).
Exception 4: Other comorbidity-driven approvals (potential future). The FDA is reviewing additional indications for GLP-1 drugs, including non-alcoholic steatohepatitis (NASH) and chronic kidney disease. If approved, those indications could create additional Part D pathways.
What Medicare Part D covers in 2026
The actual 2026 Part D coverage landscape for weight-related medications:
| Medication | Primary FDA indication | Medicare Part D coverage |
|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes | Covered for diabetes (89% of plans) |
| Wegovy (semaglutide) | Obesity, CV risk reduction | Covered only for CVD risk reduction in qualifying patients (about 38% of plans) |
| Mounjaro (tirzepatide) | Type 2 diabetes | Covered for diabetes (87% of plans) |
| Zepbound (tirzepatide) | Obesity, OSA | Covered only for moderate-to-severe OSA (about 22% of plans, growing) |
| Rybelsus (oral semaglutide) | Type 2 diabetes | Covered for diabetes (84% of plans) |
| Victoza (liraglutide) | Type 2 diabetes | Covered for diabetes (78% of plans) |
| Saxenda (liraglutide) | Obesity | Not covered |
| Trulicity (dulaglutide) | Type 2 diabetes | Covered for diabetes (86% of plans) |
| Phentermine | Obesity | Not covered |
| Orlistat (Alli, Xenical) | Obesity | Not covered |
| Naltrexone-bupropion (Contrave) | Obesity | Not covered |
| Phentermine-topiramate (Qsymia) | Obesity | Not covered |
| Setmelanotide (Imcivree) | Genetic obesity (rare) | Sometimes covered for genetic POMC, PCSK1, LEPR deficiency |
Diabetes coverage pathway: Ozempic, Mounjaro, others
Patients with type 2 diabetes have the broadest Medicare Part D access to GLP-1 medications. The qualifying criteria:
- Documented type 2 diabetes (HbA1c 6.5% or higher, or fasting glucose 126 mg/dL or higher).
- Often a documented trial of metformin first (most Part D plans require this as step-1 therapy).
- Sometimes documented inadequate glycemic control on lower-tier medications.
- Prior authorization is required by most plans (76% of Part D plans require PA for GLP-1s as of 2025).
Typical Part D copay for Ozempic, Mounjaro, or another GLP-1 for diabetes:
- Initial coverage phase: $200 to $500 per month, depending on the plan's specialty tier.
- Coverage gap (donut hole): historically higher, but the Inflation Reduction Act of 2022 eliminated the coverage gap as of January 2025. Most patients now stay in initial coverage until they hit the new $2,000 annual out-of-pocket cap.
- Catastrophic coverage: $0 after the patient hits the $2,000 annual out-of-pocket maximum (2026 figure).
The $2,000 cap is one of the more significant Medicare changes in years. For patients on Ozempic for diabetes, it means total annual out-of-pocket cost is capped, no matter how high the specialty copay is.
Cardiovascular risk pathway: Wegovy
In March 2024, the FDA expanded Wegovy's label to include cardiovascular risk reduction in adults with established cardiovascular disease and:
- BMI of 27 or higher (overweight or obesity), and
- Established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease).
This was based on the SELECT trial, which followed 17,604 patients for an average of 39.8 months. Semaglutide reduced the composite primary endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% compared to placebo.
For Medicare Part D coverage purposes, the prescription has to be written for cardiovascular risk reduction, not weight loss. The prescriber documents:
- The cardiovascular history (specific event, date, current medications).
- BMI of 27 or higher.
- Often a documented trial of standard secondary prevention (statin therapy, antiplatelet, etc).
Coverage uptake has been gradual. As of late 2025, about 38% of Part D plans had updated their formularies to cover Wegovy for CVD risk reduction. The percentage is rising as plans renegotiate contracts with Novo Nordisk.
The coverage doesn't extend to patients with obesity but no documented CVD. A 60-year-old with BMI 32 and no heart history would still face the weight-loss exclusion for Wegovy.
Sleep apnea pathway: Zepbound
In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The approval was based on the SURMOUNT-OSA trial, which showed tirzepatide significantly reduced AHI in patients with OSA.
For Medicare Part D coverage:
- Documented moderate-to-severe OSA (Apnea-Hypopnea Index of 15 or higher, confirmed by sleep study).
- BMI of 30 or higher (obesity).
- Often documentation of CPAP intolerance or failure (some plans require this).
- Prior authorization with sleep study results.
As of Q1 2026, about 22% of Part D plans have updated formularies to cover Zepbound for OSA. The percentage is expected to grow as 2026 plan-year updates roll out.
For patients with both OSA and obesity but without CPAP failure documentation, some plans deny on the grounds that CPAP should be tried first. Others approve based on AHI documentation alone.
Older weight-loss drugs and Medicare
Pre-GLP-1 weight-loss drugs are categorically excluded from Medicare Part D when prescribed for weight loss:
| Drug | FDA-approved | Covered by Medicare Part D for weight loss? |
|---|---|---|
| Phentermine (Adipex-P, Lomaira) | 1959 | No |
| Orlistat (Alli, Xenical) | 1999 | No |
| Phentermine-topiramate (Qsymia) | 2012 | No |
| Naltrexone-bupropion (Contrave) | 2014 | No |
| Liraglutide (Saxenda) | 2014 (obesity) | No |
| Semaglutide (Wegovy) | 2021 (obesity) | Only for CVD risk reduction |
| Tirzepatide (Zepbound) | 2023 (obesity) | Only for OSA |
| Setmelanotide (Imcivree) | 2020 (genetic) | Sometimes for specific genetic indications |
Patients on older drugs (e.g., phentermine for many years) typically pay cash. Phentermine retail cost is low (about $15 to $40 per month for the generic), so the cash burden is manageable. Newer obesity drugs (Wegovy, Zepbound) have monthly cash costs in the $399 to $1,250 range.
Medicare Advantage and Part C rules
Medicare Advantage plans (Part C) include a Part D component for prescription drug coverage. The same statutory exclusion applies. A Medicare Advantage plan cannot offer weight-loss drug coverage as a "supplemental" benefit, because doing so would conflict with the Part D rules.
Some Medicare Advantage plans offer:
- Diabetes management programs that may cover ancillary support (nutrition counseling, supplies).
- Weight management lifestyle programs (gym memberships, coaching).
- Bariatric surgery (covered separately under Part A or B for qualifying patients).
But the actual prescription drug for weight loss falls under the Part D exclusion regardless of which plan you're on.
Medigap, supplement plans, and weight-loss drugs
Medigap (Medicare Supplement) plans don't cover prescription drugs at all. They fill in cost-sharing gaps for Part A and Part B services. They have nothing to do with whether your weight-loss drug is covered.
If you have a Medigap plan and a separate Part D plan, the Part D rules above are what determine coverage.
If you have a "Medicare Supplement Plus Drug" arrangement, that's structurally a Part D plan and follows Part D rules.
Cost expectations even when covered
When coverage applies (diabetes, CVD risk, OSA), the actual out-of-pocket cost depends on:
- Specialty tier copay: GLP-1s are usually on a specialty tier with $200 to $500 monthly copays.
- Coverage gap: eliminated for 2025 and forward by the Inflation Reduction Act, but historically a barrier.
- Annual out-of-pocket cap: $2,000 for 2026, which caps total annual cost-sharing on covered medications.
- Plan-specific PA criteria: some plans approve fast, others require multiple submissions.
For a Medicare Part D patient on Ozempic for diabetes in 2026:
- Initial coverage phase: about $250 monthly copay.
- Once $2,000 out-of-pocket is reached (typically by month 4 to 6 on a specialty drug): $0 copay for the rest of the year.
- Annual total: capped at $2,000.
For a Medicare Part D patient on Wegovy for CVD risk reduction:
- Initial coverage phase: about $300 to $500 monthly copay.
- Once $2,000 out-of-pocket is reached: $0 copay.
- Annual total: capped at $2,000.
The $2,000 cap is the most significant Medicare cost-control mechanism in decades. For patients on GLP-1s, it limits annual exposure dramatically.
Alternatives if Medicare excludes your medication
If you're on Medicare and your prescribed weight-loss drug isn't covered, the practical options:
Option 1: Switch to a covered indication. If you have type 2 diabetes (or pre-diabetes that progresses to diabetes), the GLP-1 for diabetes pathway opens. If you have established CVD, the Wegovy CVD pathway may open. If you have moderate-to-severe OSA, the Zepbound OSA pathway may open. Talk to your provider about whether you have a covered indication.
Option 2: Manufacturer self-pay programs.
- LillyDirect Zepbound vials: $349 to $549 monthly for self-pay patients.
- NovoCare Wegovy cash program: about $499 monthly for cash-pay patients.
- These prices apply regardless of insurance status.
Option 3: Compounded GLP-1 via licensed telehealth.
- Compounded semaglutide: $179 to $279 monthly.
- Compounded tirzepatide: $200 to $400 monthly.
- Not FDA-approved. Discuss with a licensed clinician before starting.
Option 4: Older weight-loss drugs at cash price.
- Phentermine: $15 to $40 monthly (generic).
- Orlistat: $50 to $80 monthly (generic).
- Less effective than GLP-1s, but cheap.
Option 5: Appeal for an exception. Medicare allows an "exception request" if the prescribed medication is medically necessary and not covered. The success rate for weight-loss-only exceptions is low (under 5%), but it's a path for patients who've tried multiple alternatives.
FAQ
Does Medicare cover Wegovy for weight loss? No, not for weight loss alone. Medicare Part D cannot cover Wegovy for weight loss under the Social Security Act exclusion. Medicare Part D does cover Wegovy for cardiovascular risk reduction in patients with established CVD and BMI 27 or higher, after the March 2024 FDA approval.
Does Medicare cover Ozempic? Yes, for type 2 diabetes. Medicare Part D covers Ozempic when prescribed for type 2 diabetes, with prior authorization on most plans. About 89% of Part D plans cover Ozempic for diabetes. Medicare cannot cover Ozempic for weight loss.
Does Medicare cover Zepbound? Generally no, but with a sleep apnea exception. Medicare Part D cannot cover Zepbound for weight loss. After the December 2024 FDA approval for moderate-to-severe sleep apnea in patients with obesity, some Part D plans (about 22% as of Q1 2026) cover Zepbound for the OSA indication with prior authorization and sleep study documentation.
Does Medicare cover phentermine for weight loss? No. Phentermine is excluded from Medicare Part D when prescribed for weight loss. Patients pay cash, which is typically $15 to $40 per month for the generic.
Why won't Medicare cover weight loss drugs? The Medicare Modernization Act of 2003 explicitly excluded weight-loss drugs from Part D coverage. The exclusion is codified in Social Security Act Section 1860D-2(e)(2)(A). Multiple congressional attempts to amend the exclusion have not passed as of 2026.
Will Medicare ever cover weight loss drugs? Possibly. The Treat and Reduce Obesity Act (TROA) has been introduced in multiple congressional sessions and has growing bipartisan support. If passed, it would allow Part D coverage of FDA-approved chronic weight-management medications. As of Q1 2026, TROA has not passed.
Does Medicare Advantage cover weight loss drugs? No. Medicare Advantage plans include Part D coverage but follow the same exclusion rules. A Medicare Advantage plan cannot offer weight-loss drug coverage as a supplemental benefit.
Can I get Wegovy on Medicare if I have heart disease? Possibly, for cardiovascular risk reduction. After the March 2024 FDA approval, Wegovy can be prescribed for CVD risk reduction in patients with BMI 27 or higher and established CVD. About 38% of Part D plans cover Wegovy for this indication with prior authorization.
Does Medicaid cover weight loss drugs? Varies by state. About 14 states cover GLP-1s for obesity through Medicaid as of late 2025. The rest exclude or restrict. Check your state's preferred drug list.
How much does Ozempic cost on Medicare? Specialty tier copay typically runs $200 to $500 per month. With the 2025/2026 Inflation Reduction Act $2,000 annual out-of-pocket cap, total annual cost is capped regardless of how many fills you need.
Does Medicare cover Saxenda? No. Saxenda (liraglutide for obesity) is excluded under the weight-loss-only category. The same molecule sold as Victoza for diabetes is covered by most Part D plans.
Can I appeal a Medicare denial for weight-loss drugs? You can file an exception request. The success rate for weight-loss-only exceptions is low (under 5%) because the underlying exclusion is statutory. Appeals are more successful when the prescription is for a covered indication (diabetes, CVD, OSA) and the denial is based on documentation.
What weight-loss drugs are excluded from Medicare? Phentermine, orlistat (Alli, Xenical), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy except for CVD risk reduction), tirzepatide (Zepbound except for OSA), and any other drug whose primary FDA indication is weight loss.
Sources
- Social Security Act Section 1860D-2(e)(2)(A). Drug exclusions under Medicare Part D.
- Centers for Medicare and Medicaid Services. Part D Drug Coverage Exclusions. 42 CFR 423.100.
- Medicare Modernization Act of 2003. Public Law 108-173.
- Inflation Reduction Act of 2022. Public Law 117-169 (Medicare Part D out-of-pocket cap provisions).
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Malhotra A, et al. Tirzepatide for treatment of OSA and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
- U.S. Food and Drug Administration. Wegovy Label Expansion (Cardiovascular Risk Reduction). March 2024.
- U.S. Food and Drug Administration. Zepbound Label Expansion (Obstructive Sleep Apnea). December 2024.
- KFF. Medicare Part D Coverage of GLP-1 Medications. 2025.
- Treat and Reduce Obesity Act (TROA). H.R. 4818, S. 2407 (118th Congress).
- Mercer Health and Benefits. National Survey of Employer-Sponsored Health Plans. 2025.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda are registered trademarks of Novo Nordisk. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly. Adipex-P, Lomaira, Alli, Xenical, Qsymia, Contrave, and Imcivree are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →